US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Regentis Biomaterials Ltd.

2.38

+0.16007.21%

Post-market: 2.29-0.0900-3.78%19:57 EDT

Volume:107.69K

Turnover:258.45K

Market Cap:16.75M

PE:-0.10

High:2.56

Open:2.22

Low:2.10

Close:2.22

52wk High:15.50

52wk Low:1.23

Shares:7.04M

Float Shares:4.84M

Volume Ratio:0.74

T/O Rate:2.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-24.1591

EPS(LYR):-24.1600

ROE:--

ROA:-107.53%

PB:3.53

PE(LYR):-0.10

Loading ...

Overview Company News Filings

Regentis Biomaterials Director Efraim Cohen-Arazi Files Initial Beneficial Ownership Statement

Regentis Biomaterials director Jeff Dykan files initial beneficial ownership statement

Regentis Biomaterials CFO Gon Ori files initial beneficial ownership statement

Regentis Biomaterials Ltd. files Form 3 as Chief Accounting Officer Arie Gordashnikov reports no beneficial ownership

Regentis Biomaterials Director Pini Ben-Elazar Files Initial Beneficial Ownership Statement

NYSE American New 52-Week Highs And Lows

Regentis Biomaterials initiated with a Buy at ThinkEquity

Regentis reports FY 2025 G&A expense USD 6.6 million, up 832.2%

Regentis reports FY 2025 operating expenses of USD 7.0 million

Regentis Biomaterials appoints Galit Reke as CMO

Regentis Biomaterials Expands European Clinical Network Ahead of 2026 GelrinC Launch

Amex Halt Add Info Lst 4.080000

THOMSON REUTERS

Regentis Biomaterials Taps New CFO/Chief Business Officer as GelrinC Nears EU Launch and Midpoint of U.S. Phase III Trial

Regentis Biomaterials appoints Ori Gon as CFO, CBO

Regentis Biomaterials Expands U.S. Phase III GelrinC Trial Network After Enrollment Surpasses Midpoint

Amex Halt Add Info Lst 4.810000

THOMSON REUTERS

Amex Halt Add Info Lst 5.650000

THOMSON REUTERS

Regentis’ GelrinC Shows Native-Like Cartilage Regeneration in 2-Year MRI Data

Regentis Biomaterials' GelrinC Shows Native-Like Cartilage Regeneration in Knee Repair Clinical Trial

Regentis Biomaterials Ltd trading halted, volatility trading pause

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RGNT/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RGNT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RGNT\",,,,,undefined,":{"symbol":"RGNT","market":"US","secType":"STK","nameCN":"Regentis Biomaterials Ltd.","latestPrice":2.38,"timestamp":1784318400000,"preClose":2.22,"halted":0,"volume":107694,"hourTrading":{"tag":"盘后","latestPrice":2.29,"preClose":2.38,"latestTime":"19:57 EDT","volume":3014,"amount":6925.3718,"timestamp":1784332637750,"change":-0.09,"changeRate":-0.037815,"amplitude":0.042017},"delay":0,"changeRate":0.07207207207207193,"floatShares":4842164,"shares":7036500,"eps":-24.159056,"marketStatus":"Market Closed","change":0.16,"latestTime":"07-17 16:00:00 EDT","open":2.22,"high":2.56,"low":2.1,"amount":258446.915091,"amplitude":0.207207,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-24.159056,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1784534400000},"marketStatusCode":7,"adr":0,"listingDate":1764824400000,"exchange":"AMEX","adjPreClose":2.22,"preHourTrading":{"tag":"盘前","latestPrice":2.2482,"preClose":2.22,"latestTime":"09:14 EDT","volume":1831,"amount":4201.9426745,"timestamp":1784294094017,"change":0.0282,"changeRate":0.012703,"amplitude":0.18018},"postHourTrading":{"tag":"盘后","latestPrice":2.29,"preClose":2.38,"latestTime":"19:57 EDT","volume":3014,"amount":6925.3718,"timestamp":1784332637750,"change":-0.09,"changeRate":-0.037815,"amplitude":0.042017},"volumeRatio":0.7410837904356272},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RGNT\",,,,,undefined,":{"symbol":"RGNT","floatShares":4842164,"roa":"-107.53%","roe":"--","lyrEps":-24.159999,"volumeRatio":0.7410837904356272,"shares":7036500,"dividePrice":0,"high":2.56,"amplitude":0.207207,"preClose":2.22,"low":2.1,"week52Low":1.2316,"pbRate":"3.53","week52High":15.5,"institutionHeld":0,"latestPrice":2.38,"eps":-24.159056,"divideRate":0,"volume":107694,"delay":0,"ttmEps":-24.159056,"open":2.22,"prevYearClose":6.74,"prevWeekClose":3.79,"prevMonthClose":3.53,"prevQuarterClose":3.53,"fiveDayClose":3.79,"twentyDayClose":4.75,"sixtyDayClose":2.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RGNT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RGNT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RGNT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RGNT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RGNT","date":"2026-07-17","current":-0.098514,"percent":0.825301,"low":-9.624274,"twenty":-6.113394,"median":-1.339625,"eighty":-0.916106,"high":11.294138,"avg":-2.582306,"sd":3.728218,"marketCap":11498219},"quantilePoints":[{"date":"2025-09-12","current":11.294138,"twenty":11.294138,"median":11.294138,"eighty":11.294138,"marketCap":54223158},{"date":"2025-09-17","current":11.294138,"twenty":11.294138,"median":11.294138,"eighty":11.294138,"marketCap":54223158},{"date":"2025-11-14","current":-9.624274,"twenty":-1.256909,"median":11.294138,"eighty":11.294138,"marketCap":54223158},{"date":"2025-11-20","current":-9.624274,"twenty":-9.624274,"median":11.294138,"eighty":11.294138,"marketCap":54223158},{"date":"2025-11-26","current":-9.624274,"twenty":-9.624274,"median":-9.624274,"eighty":11.294138,"marketCap":54223158},{"date":"2025-12-05","current":-6.894806,"twenty":-9.624274,"median":-7.354459,"eighty":11.294138,"marketCap":38845335},{"date":"2025-12-12","current":-6.563855,"twenty":-9.624274,"median":-6.89021,"eighty":11.294138,"marketCap":36980758},{"date":"2025-12-19","current":-5.880074,"twenty":-9.624274,"median":-6.600627,"eighty":11.294138,"marketCap":33128337},{"date":"2025-12-26","current":-6.113394,"twenty":-9.624274,"median":-6.527083,"eighty":1.180569,"marketCap":34442863},{"date":"2026-01-02","current":-6.196132,"twenty":-8.716348,"median":-6.3708,"eighty":-5.580196,"marketCap":34909007},{"date":"2026-01-09","current":-6.352414,"twenty":-7.170598,"median":-6.31555,"eighty":-5.626198,"marketCap":35789501},{"date":"2026-01-16","current":-7.078667,"twenty":-7.005123,"median":-6.260483,"eighty":-5.72734,"marketCap":39881210},{"date":"2026-01-23","current":-6.664979,"twenty":-6.894806,"median":-6.333844,"eighty":-5.846096,"marketCap":37550490},{"date":"2026-01-30","current":-5.635354,"twenty":-6.892967,"median":-6.278869,"eighty":-5.846096,"marketCap":31749587},{"date":"2026-02-06","current":-4.421869,"twenty":-6.856195,"median":-6.196132,"eighty":-5.571003,"marketCap":24912808},{"date":"2026-02-13","current":-4.026566,"twenty":-6.723814,"median":-6.113762,"eighty":-5.331983,"marketCap":22685675},{"date":"2026-02-20","current":-3.594492,"twenty":-6.664979,"median":-6.113394,"eighty":-4.421869,"marketCap":20251367},{"date":"2026-02-27","current":-1.495219,"twenty":-6.600627,"median":-6.113394,"eighty":-4.026566,"marketCap":20406749},{"date":"2026-03-06","current":-1.271316,"twenty":-6.563855,"median":-6.053639,"eighty":-3.612878,"marketCap":17350916},{"date":"2026-03-13","current":-1.282663,"twenty":-6.527083,"median":-5.880074,"eighty":-1.504175,"marketCap":17505779},{"date":"2026-03-20","current":-1.196479,"twenty":-6.527083,"median":-5.644593,"eighty":-1.282663,"marketCap":16329542},{"date":"2026-03-27","current":-1.153672,"twenty":-6.526991,"median":-5.56181,"eighty":-1.271316,"marketCap":15745309},{"date":"2026-04-02","current":-1.138492,"twenty":-6.505001,"median":-5.341176,"eighty":-1.230216,"marketCap":15538134},{"date":"2026-04-10","current":-1.159364,"twenty":-6.396541,"median":-4.971155,"eighty":-1.194415,"marketCap":15822999},{"date":"2026-04-17","current":-1.214391,"twenty":-6.356091,"median":-4.421869,"eighty":-1.179477,"marketCap":16574009},{"date":"2026-04-24","current":-1.168851,"twenty":-6.34506,"median":-4.136653,"eighty":-1.176433,"marketCap":15952484},{"date":"2026-05-01","current":-1.104337,"twenty":-6.335719,"median":-3.755371,"eighty":-1.159364,"marketCap":15071989},{"date":"2026-05-08","current":-0.865254,"twenty":-6.326637,"median":-3.645054,"eighty":-1.156707,"marketCap":11808981},{"date":"2026-05-15","current":-0.777969,"twenty":-6.302772,"median":-3.401437,"eighty":-1.138492,"marketCap":10617724},{"date":"2026-05-22","current":-0.815919,"twenty":-6.267838,"median":-1.499697,"eighty":-1.134697,"marketCap":11135662},{"date":"2026-05-29","current":-0.751404,"twenty":-6.243936,"median":-1.282663,"eighty":-1.110409,"marketCap":10255168},{"date":"2026-06-05","current":-0.652735,"twenty":-6.210841,"median":-1.277843,"eighty":-0.952538,"marketCap":8908530},{"date":"2026-06-12","current":-0.721045,"twenty":-6.196132,"median":-1.273213,"eighty":-0.865254,"marketCap":9840818},{"date":"2026-06-18","current":-1.802612,"twenty":-6.163331,"median":-1.275111,"eighty":-0.865254,"marketCap":24602045},{"date":"2026-06-26","current":-1.574913,"twenty":-6.113836,"median":-1.282663,"eighty":-0.878916,"marketCap":21494418},{"date":"2026-07-02","current":-1.734302,"twenty":-6.113394,"median":-1.282663,"eighty":-0.902444,"marketCap":23669757},{"date":"2026-07-10","current":-1.38137,"twenty":-6.113394,"median":-1.369985,"eighty":-0.917624,"marketCap":18852935},{"date":"2026-07-17","current":-0.842484,"twenty":-6.113394,"median":-1.339625,"eighty":-0.916106,"marketCap":11498219}],"updateTime":1784425146319},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RGNT\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620262772","title":"Regentis Biomaterials Director Efraim Cohen-Arazi Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262772","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262772?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:31","pubTimestamp":1773865882,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials filed an initial statement of beneficial ownership on behalf of Efraim Cohen-Arazi. He is listed as a director. The filing stated that no securities are beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4HkFBl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620262701","title":"Regentis Biomaterials director Jeff Dykan files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262701","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262701?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:31","pubTimestamp":1773865881,"startTime":"0","endTime":"0","summary":"Jeff Dykan, a director of Regentis Biomaterials, filed an initial statement of beneficial ownership. The filing reported indirect beneficial ownership of 270,473 ordinary shares. It also reported indirect beneficial ownership of 130,465 ordinary shares. The filing listed warrants exercisable at USD 5 for 6,122 ordinary shares. It also listed warrants exercisable at USD 5 for 2,083 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9Hp74n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620620862","title":"Regentis Biomaterials CFO Gon Ori files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620620862","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620620862?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:31","pubTimestamp":1773865880,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials filed an initial statement of beneficial ownership naming Ori Gon as chief financial officer. The filing reported an employee stock option for 84,951 shares of common stock. The option exercise price was USD 4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbc2Ns2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620039262","title":"Regentis Biomaterials Ltd. files Form 3 as Chief Accounting Officer Arie Gordashnikov reports no beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2620039262","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620039262?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:31","pubTimestamp":1773865875,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials filed an initial statement of beneficial ownership naming Arie Gordashnikov as Chief Accounting Officer. The filing reported that Gordashnikov beneficially owned no securities as of 03/18/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL1yhpZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620262718","title":"Regentis Biomaterials Director Pini Ben-Elazar Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262718","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262718?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:30","pubTimestamp":1773865856,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials reported that director Pini Ben-Elazar filed an initial statement of beneficial ownership. Ben-Elazar reported direct ownership of 128,666 ordinary shares. He also reported an employee stock option for 39,295 shares with an exercise price of USD 0.01. Ben-Elazar reported warrants for 15,831 shares with an exercise price of USD 5.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5HK7wR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620607476","title":"NYSE American New 52-Week Highs And Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2620607476","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620607476?lang=en_us&edition=fundamental","pubTime":"2026-03-17 23:20","pubTimestamp":1773760800,"startTime":"0","endTime":"0","summary":"COMPANY                      SYMBOL       HIGH         VOLUME. -------                      ------       ----         ------. Imperial Oil                 IMO        125.44        209,995. COMPANY                      SYMBOL       LOW          VOLUME. -------                      ------       ----         ------. Credit Suisse Income Fnd     CIK          2.56         35,683. Green Circle Decarbonize     GCDT         1.80          9,147. NFT                          MI         0.5051        192,534. Nasus Pharma                 NSRX         2.70        278,185. Nuburu                       BURU       0.1756     10,216,696. Regentis Biomaterials        RGNT         3.00            810. Serina Therapeutics          SER          1.39         11,876. Copyright (c) 2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4117","NYSE","NSRX","BK4007","AFG","BK4139","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616336001","title":"Regentis Biomaterials initiated with a Buy at ThinkEquity","url":"https://stock-news.laohu8.com/highlight/detail?id=2616336001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616336001?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:39","pubTimestamp":1772451591,"startTime":"0","endTime":"0","summary":"ThinkEquity initiated coverage of Regentis Biomaterials (RGNT) with a Buy rating and $10 price target Regentis is a single-asset medtech company ad...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-initiated-with-a-buy-at-thinkequity-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-initiated-with-a-buy-at-thinkequity-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614239737","title":"Regentis reports FY 2025 G&A expense USD 6.6 million, up 832.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614239737","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614239737?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:32","pubTimestamp":1771968770,"startTime":"0","endTime":"0","summary":"Regentis reported a FY 2025 net loss and comprehensive loss of USD 13.6 million, with an operating loss of USD 7.0 million and finance expense, net of USD 6.7 million. General and administrative expenses rose to USD 6.6 million , driven mainly by USD 5.4 million in non-cash share-based compensation tied to 2025 option grants and a special IPO-related bonus, while R&D expense was USD 331,000  following the completion of the Horizon 2020 grant funding in 2024. The company said it has not recognized any revenue to date and does not expect material revenue in the near term. Cash and cash equivalents were USD 7.4 million as of Dec. 31, 2025, and net cash used in operating activities was USD 1.4 million for FY 2025. Regentis said its cash is expected to fund operations through February 2027, and highlighted the Dec. 5, 2025 IPO of 1,250,000 ordinary shares at USD 8.00 per share for gross proceeds of about USD 10 million. On the business side, Regentis reiterated its focus on orthopedic tissu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL30m9wN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614372364","title":"Regentis reports FY 2025 operating expenses of USD 7.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614372364","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614372364?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:27","pubTimestamp":1771968472,"startTime":"0","endTime":"0","summary":"Regentis reported FY 2025 results, highlighting operating expenses of USD 7.0 million for the year ended Dec. 31, 2025, including USD 5.3 million in non-cash expenses. Cash and equivalents were USD 7.4 million as of Dec. 31, 2025; the company said this is expected to provide runway to complete site expansion and patient enrollment for its pivotal Phase III FDA trial of GelrinC in knee cartilage repair, with patient enrollment surpassing 50% and potential completion of recruitment and treatment by mid-2026. During the period, Regentis completed an IPO that closed on Dec. 5, 2025, raising gross proceeds of USD 10 million, and established 7 new U.S. clinical sites and 6 new European clinical sites. The company said GelrinC, already approved in Europe, is expected to be rolled out in clinics across Europe in 2026. Regentis also reported publication of GelrinC data in the journal Cartilage using MOCART MRI assessment, and said it received its 27th patent for the Gelrin platform technology, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL9vLHWw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612288759","title":"Regentis Biomaterials appoints Galit Reke as CMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2612288759","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612288759?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:57","pubTimestamp":1771509458,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials (RGNT) announced the appointment of Dr. Galit Reske as Chief Medical Officer. Dr. Reske brings extensive experience in clinic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-appoints-galit-reke-as-cmo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-appoints-galit-reke-as-cmo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612463357","title":"Regentis Biomaterials Expands European Clinical Network Ahead of 2026 GelrinC Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2612463357","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612463357?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:57","pubTimestamp":1771340236,"startTime":"0","endTime":"0","summary":"An update from Regentis Biomaterials Ltd ( ($RGNT) ) is now available. On February 17, 2026, Regentis Biomaterials announced it has expanded its Eu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regentis-biomaterials-expands-european-clinical-network-ahead-of-2026-gelrinc-launch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regentis-biomaterials-expands-european-clinical-network-ahead-of-2026-gelrinc-launch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611751629","title":"Amex Halt  Add Info Lst 4.080000","url":"https://stock-news.laohu8.com/highlight/detail?id=2611751629","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611751629?lang=en_us&edition=fundamental","pubTime":"2026-02-13 00:55","pubTimestamp":1770915312,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nAQN2LM236:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609374765","title":"Regentis Biomaterials Taps New CFO/Chief Business Officer as GelrinC Nears EU Launch and Midpoint of U.S. Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374765","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609374765?lang=en_us&edition=fundamental","pubTime":"2026-02-05 19:57","pubTimestamp":1770292666,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials Ltd ( ($RGNT) ) just unveiled an announcement. On February 4, 2026, Regentis Biomaterials appointed Ori Gon as Chief Financia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regentis-biomaterials-taps-new-cfo-chief-business-officer-as-gelrinc-nears-eu-launch-and-midpoint-of-u-s-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regentis-biomaterials-taps-new-cfo-chief-business-officer-as-gelrinc-nears-eu-launch-and-midpoint-of-u-s-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGNT","BK4156","BK4134","BK4139","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608536744","title":"Regentis Biomaterials appoints Ori Gon as CFO, CBO","url":"https://stock-news.laohu8.com/highlight/detail?id=2608536744","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608536744?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:01","pubTimestamp":1770213694,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials (RGNT) announced the appointment of Ori Gon as CFO and CBO. Gon will lead the Company’s commercial and business development a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-appoints-ori-gon-as-cfo-cbo-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-appoints-ori-gon-as-cfo-cbo-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607352020","title":"Regentis Biomaterials Expands U.S. Phase III GelrinC Trial Network After Enrollment Surpasses Midpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2607352020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607352020?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:41","pubTimestamp":1769697700,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials Ltd ( ($RGNT) ) has shared an update. On January 29, 2026, Regentis Biomaterials announced it is expanding its U.S. clinical ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regentis-biomaterials-expands-u-s-phase-iii-gelrinc-trial-network-after-enrollment-surpasses-midpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regentis-biomaterials-expands-u-s-phase-iii-gelrinc-trial-network-after-enrollment-surpasses-midpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RGNT","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607745396","title":"Amex Halt  Add Info Lst 4.810000","url":"https://stock-news.laohu8.com/highlight/detail?id=2607745396","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607745396?lang=en_us&edition=fundamental","pubTime":"2026-01-29 00:25","pubTimestamp":1769617506,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nAQN2LJNWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607743281","title":"Amex Halt  Add Info Lst 5.650000","url":"https://stock-news.laohu8.com/highlight/detail?id=2607743281","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607743281?lang=en_us&edition=fundamental","pubTime":"2026-01-29 00:04","pubTimestamp":1769616291,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nAQN2LJNX0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604117601","title":"Regentis’ GelrinC Shows Native-Like Cartilage Regeneration in 2-Year MRI Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2604117601","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604117601?lang=en_us&edition=fundamental","pubTime":"2026-01-20 22:38","pubTimestamp":1768919898,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials Ltd ( ($RGNT) ) has provided an update. On January 20, 2026, Regentis Biomaterials announced new long-term MRI data from a co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regentis-gelrinc-shows-native-like-cartilage-regeneration-in-2-year-mri-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regentis-gelrinc-shows-native-like-cartilage-regeneration-in-2-year-mri-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604199141","title":"Regentis Biomaterials' GelrinC Shows Native-Like Cartilage Regeneration in Knee Repair Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2604199141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604199141?lang=en_us&edition=fundamental","pubTime":"2026-01-20 22:09","pubTimestamp":1768918169,"startTime":"0","endTime":"0","summary":"Regentis Biomaterials Ltd. has announced new long-term imaging data from a completed European clinical trial of its GelrinC device for knee cartilage repair. The results, published in the peer-reviewed journal Cartilage, show that patients treated with GelrinC demonstrated regenerated cartilage with internal structural organization closely resembling healthy, native hyaline cartilage after 24 months. The MRI analysis, conducted using validated methodologies accepted by both the U.S. FDA and the European EMA, indicated that the repaired tissue exhibited a layered architecture similar to native cartilage. GelrinC is currently approved for commercialization in Europe with a CE Mark, and a Phase III U.S. FDA study is ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL8WnFZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604997703","title":"Regentis Biomaterials Ltd trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2604997703","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604997703?lang=en_us&edition=fundamental","pubTime":"2026-01-17 00:00","pubTimestamp":1768579215,"startTime":"0","endTime":"0","summary":"10:56 EST Regentis Biomaterials (RGNT) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-ltd-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regentis-biomaterials-ltd-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":61,"code":"91000000","status":"200"}]}}